

A Mutation in the *CASQ1* Gene Causes a Vacuolar Myopathy with Accumulation of Sarcoplasmic Reticulum Protein Aggregates

Daniela Rossi,^{1,2} Bianca Vezzani,¹ Lucia Galli,¹ Cecilia Paolini,^{2,3} Luana Toniolo,⁴ Enrico Pierantozzi,¹ Simone Spinozzi,¹ Virginia Barone,^{1,2} Elena Pegoraro,⁵ Luca Bello,⁵ Giovanna Cenacchi,⁶ Gaetano Vattemi,⁷ Giuliano Tomelleri,⁷ Giulia Ricci,⁸ Gabriele Siciliano,⁸ Feliciano Protasi,^{2,3} Carlo Reggiani,^{2,4,9} and Vincenzo Sorrentino^{1,2*}

¹Molecular Medicine Section, Department of Molecular and Developmental Medicine, University of Siena and Azienda Ospedaliera Universitaria Senese, Siena 53100, Italy; ²IIM, Interuniversity Institute of Myology; ³Ce.S.I., Center for Research on Ageing & DNICS, Department of Neuroscience, Imaging, and Clinical Sciences, University G. D'Annunzio, Chieti 66013, Italy; ⁴Department of Biomedical Sciences, University of Padova, Padova 35131, Italy; ⁵Department of Neurosciences, University of Padova, Padova 35131, Italy; ⁶Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna 40138, Italy; ⁷Department of Neurological and Movement Sciences, University of Verona, Verona 37129, Italy; ⁸Department of Clinical and Experimental Medicine, University of Pisa, Pisa 56126, Italy; ⁹CNR Institute of Neuroscience, Padova 35131, Italy

Communicated by Hamish S. Scott

Received 16 June 2014; accepted revised manuscript 5 August 2014.

Published online 12 August 2014 in Wiley Online Library (www.wiley.com/humanmutation). DOI: 10.1002/humu.22631

ABSTRACT: A missense mutation in the calsequestrin-1 gene (*CASQ1*) was found in a group of patients with a myopathy characterized by weakness, fatigue, and the presence of large vacuoles containing characteristic inclusions resulting from the aggregation of sarcoplasmic reticulum (SR) proteins. The mutation affects a conserved aspartic acid in position 244 (p.Asp244Gly) located in one of the high-affinity Ca²⁺-binding sites of *CASQ1* and alters the kinetics of Ca²⁺ release in muscle fibers. Expression of the mutated *CASQ1* protein in COS-7 cells showed a markedly reduced ability in forming elongated polymers, whereas both in cultured myotubes and in *in vivo* mouse fibers induced the formation of electron-dense SR vacuoles containing aggregates of the mutant *CASQ1* protein that resemble those observed in muscle biopsies of patients. Altogether, these results support the view that a single missense mutation in the *CASQ1* gene causes the formation of abnormal SR vacuoles containing aggregates of *CASQ1*, and other SR proteins, results in altered Ca²⁺ release in skeletal muscle fibers, and, hence, is responsible for the clinical phenotype observed in these patients.

Hum Mutat 35:1163–1170, 2014. © 2014 Wiley Periodicals, Inc.

KEY WORDS: aggregate myopathy; *CASQ1*; calsequestrin; sarcoplasmic reticulum; skeletal muscle

Introduction

Calsequestrin (*CASQ*), a high-capacity, moderate-affinity Ca²⁺-binding protein, is the main Ca²⁺ buffer of the sarcoplasmic reticulum (SR) of cardiac and skeletal muscle [MacLennan and Wong, 1971; Damiani et al., 1990]. *CASQ* exists in two isoforms coded by distinct genes: *CASQ1* (MIM #114250), predominant in fast skeletal muscle fibers, and *CASQ2* (MIM #114251), predominant in slow skeletal muscle fibers and in cardiac muscle [Schiaffino and Reggiani, 2011]. Both in skeletal and cardiac muscles, *CASQ* is part of a multiprotein complex associated with the SR Ca²⁺ release channel, ryanodine receptor [Rossi et al., 2008], that participates in the mechanism of excitation–contraction coupling, which links T-tubule membrane depolarization to activation of Ca²⁺ release from the SR. In skeletal muscles, this mechanism occurs in specialized intracellular junctions named either triads or Ca²⁺ release units [Rossi and Dirksen, 2006]. Mutations in the *CASQ2* gene have been associated to an autosomal-recessive form of catecholaminergic polymorphic ventricular tachycardia (CPVT) [Lahat et al., 2001], whereas, so far, no disease has been associated to *CASQ1* mutations. The presence of vacuoles-containing inclusions that stain positive for *CASQ* has been reported in muscle biopsies from patients with an uncharacterized form of myopathy [Tomelleri et al., 2006]. More recently, a potential role of *CASQ1* in human diseases has been proposed based on the evidence that *CASQ1*-null mice develop lethal episodes similar to malignant hyperthermia (MH) following heat stress and halothane exposure [Dainese et al., 2009; Protasi et al., 2011]. MH is an autosomal-dominant pharmacogenetic disorder triggered by volatile anesthetics, which in about 80% of the affected individuals is caused by mutations in the *RYR1* gene (MIM #180901) [Galli et al., 2006]. Up to now, mutation screening in MH patients did not result in identification of causative mutations in *CASQ1* [Kraeva et al., 2013; V.S. and L.G., unpublished data]. Here, we report the identification of the first mutation in the *CASQ1* gene in patients with a myopathy characterized by protein aggregates containing *CASQ1*.

Additional Supporting Information may be found in the online version of this article.

*Correspondence to: Vincenzo Sorrentino, Department of Developmental and Molecular Medicine, University of Siena, Via A. Moro 2, 53100 Siena, Italy. E-mail: vincenzo.sorrentino@unisi.it

Contract grant sponsors: Telethon (GGP13213); US National Institute of Health (AR059646 and AR053349); Ministero dell' Istruzione, dell' Università e della Ricerca, Fondo Innovazione in Ricerca.

Materials and Methods

Patients and Ethics Statement

Eight patients (six males and two females), aged between 23 and 58 years, with mild myopathy participated in this study. Ethics committee approval and written informed consent were obtained for all patients. This study complies with the ethical standards laid down in the 1964 Declaration of Helsinki. All experiments that required animals followed the official guidelines laid down by the European Community Council (directive 86/609/EEC) incorporated into Italian Government Legislation. Experiments have been performed with the approval by the Local Ethical Committee and Ministero della Salute, Rome, Italy.

Genetic Analysis

Genomic DNA was extracted from peripheral blood leucocytes by standard procedures [Galli et al., 2006]. Primers were designed to amplify all exons of the *CASQ1* gene (NC_000001.11) with primer-3 software (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). Amplified DNA fragments were directly sequenced using an ABI Prism 310 apparatus (Applied Biosystem, Foster City, CA) as previously described [Galli et al., 2006]. DNA mutation numbering was based on cDNA reference sequence (NM_001231.4), taking nucleotide +1 as the A of the ATG translation initiation codon. The mutation nomenclature follows that described at the <http://www.hgvs.org/mutnomen/>. The *CASQ1* variant (NM_001231.4:c.731A>G) has been submitted to the locus-specific database (www.lovd.nl/CASQ1). Mutation screening of the *RyR1* gene was performed as previously described in Galli et al. (2006). Haplotype analysis was based on the following intra-genic SNPs: rs617698, rs61803844, rs617599, rs3747621, rs3747622, rs3747623, and rs822450.

Sequence Alignment and Protein Structure

Sequence alignment was performed using the ClustalW software (<http://www.ebi.ac.uk/Tools/msa/clustalw2/>). A three-dimensional structure of *CASQ1* p.Asp244Gly was predicted using the automated protein homology modeling server SWISS-MODEL (<http://swissmodel.expasy.org/>). Chain A of human *CASQ1* protein (PDB: 3UOM) was used as template. The comparison between wild-type *CASQ1* and the p.Asp244Gly *CASQ1* variant was performed using the UCSF Chimera 1.9 software (University of California).

Histology and Histochemistry of Patients' Muscle Biopsies

All patients underwent an open biopsy of vastus lateralis muscle. Muscle specimens were cryofixed in Optimal Cutting Temperature (OCT) compound (Tissue-Tek-Sakura, Sakura Finetek, Torrance, CA) by immersion in liquid nitrogen-cooled isopentane and stored at -80°C . Serial 10- μm -thick transversal or longitudinal sections were stained with haematoxylin and eosin (H&E), toluidine blue, modified Gomori trichrome, and reduced nicotinamide adenine dinucleotide (NADH), as previously described [Boncompagni et al., 2006; Tomelleri et al., 2006].

Preparation of Samples for Electron Microscopy

Muscle specimens were fixed in 3.5% glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4, room temperature) for 2 hr fol-

lowed by buffer rinse and postfixation for 1 hr in 2% osmium tetroxide. The specimens were rapidly dehydrated in graded ethanol and acetone, infiltrated with EPON-acetone (1:1) mixture for 2 hr, and embedded in EPON [Tomasi et al., 2012]. Ultrathin sections (40–50 nm) were cut and, after staining with 4% uranyl acetate and lead citrate, examined with a Morgagni Series 268D electron microscope (FEI Company, Brno, Czech Republic), equipped with a Megaview III digital camera [Boncompagni et al., 2006; Tomelleri et al., 2006]. The quantitative analysis of Ca^{2+} release units was performed in a biopsy from a patient (family 3:II-3), whereas age-matched samples were used as controls [Boncompagni et al., 2006]. Electron micrographs of nonoverlapping regions were randomly collected at the following magnifications: 18,000 \times for qualitative analysis of Ca^{2+} release unit number and 28,000 \times for the measurements of the size of SR-terminal cisternae. The frequency of triads and their morphology (discriminating between triads and dyads) and the average size of SR-terminal cisternae lumen were determined as previously described [Boncompagni et al., 2006].

Immunofluorescence

Serial 8- μm -thick transversal cryosections or single fibers from human skeletal muscle were fixed with 3% (v/v) paraformaldehyde (Sigma-Aldrich, St. Louis, MO) in phosphate-buffered saline (PBS) and permeabilized in HEPES-Triton Buffer (20 mM HEPES pH 7.4, 300 mM sucrose, 50 mM NaCl, 3 mM MgCl_2 , 0.5% Triton X-100). Cryosections or single fibers were incubated with the following primary antibodies: anti-*CASQ1* mouse monoclonal antibody diluted 1:300 (clone MA3-913; Thermo Scientific), anti-RyR mouse monoclonal antibody at a final concentration of 1 $\mu\text{g}/\text{ml}$ (clone 34C; Thermo Scientific, Waltham, MA), anti-RyR1 rabbit polyclonal antibody [Rossi et al., 2014], and anti-SERCA monoclonal antibody diluted 1:1 (clone Y/IF4 kindly provided by Prof. M. East). Cy3- or Cy2-conjugated antimouse or antirabbit secondary antibodies (Jackson Laboratories, Bar Harbor, ME) were used for immunofluorescence detection. Images were acquired using a confocal laser scanning microscope (Carl Zeiss, Oberkochen, Germany).

African green monkey kidney-derived COS-7 cells grown on glass coverslips and transfected with *CASQ1*^{MUT}-GFP or *CASQ1*^{WT}-GFP (see *Generation of CASQ1 Expression Vectors*) were fixed after 24 hr from transfection with 3% (v/v) paraformaldehyde in PBS. Myotubes expressing *CASQ1*^{MUT} or *CASQ1*^{WT} were fixed after 12 days of differentiation with 3% (v/v) paraformaldehyde in PBS and permeabilized in HEPES-Triton buffer. Cells were incubated with the previously described primary antibodies.

Single Fiber Ca^{2+} Release and Force Measurement

Small fragments of biopsy specimens were immersed in glycerol-containing skinning solution [Salviati and Volpe, 1988] for at least 24 hr. Single fibers were manually dissected and segments of approximately 1-mm length were cut and mounted with small aluminum clips (T clips) at both ends. The experimental setup was composed of a force transducer (AE 801; Sensoror, Horten, Norway), an electromagnetic puller to control fiber length and an aluminum plate, where seven small chambers (100 μl) were milled, as previously described [Doria et al., 2011]. Fibers were mounted between the force transducer and the electromagnetic puller in the first chamber filled with relaxing solution. Next, the SR was loaded by moving the fiber to a chamber containing solution at pCa 6.45 in the presence of 5 mM ATP. After the fibers were washed to remove excess EGTA, calcium release was induced by transferring the fibers to a release

solution with low EGTA (0.1 mM) and low free Mg^{2+} -containing caffeine in concentrations variable from 0.1 to 20 mM. The fibers were finally transferred to activating solution to measure their ability to develop force during a maximal activation (pCa 4.7) and quickly brought back to the relaxing solution to start a new cycle of loading and release. The release of calcium was detected by the transient tension development and quantified by measuring the tension-time area according to a method first developed by Endo and Iino (1988) and widely used. The transient is determined by the combination of the calcium release from the SR with the calcium removal due to diffusion into the medium, buffering by EGTA, and reuptake in the SR [Makabe et al., 1996]. Experimental and model analyses suggest that the area gives the best indication on the amount of calcium release, whereas other parameters such as the rate of tension rise is more related to the rates of calcium release and of tension generation by cross-bridges. The tension-time area was normalized to the tension developed during maximal activation (pCa 4.7) to account for the ability of the myofibrillar apparatus to develop force and thus expressed in seconds.

Generation of CASQ1 Expression Vectors

Human CASQ1 cDNA (NM_001231.4) was amplified from total RNA extracted from human skeletal muscle tissue using specific primers. The cDNA coding for the Asp244Gly CASQ1 mutant (CASQ1^{MUT}) was generated by PCR using primers designed to introduce the adenosine to guanosine nucleotide change into the wild-type CASQ1 cDNA (forward primer: 5'-gtg acc atc cca gGc aag ccc aat agc-3'; reverse primer: 5'-gct att ggg ctt gGc tgg gat ggt cac-3') and sequenced using an ABI Prism 310 apparatus (Applied Biosystems). The amplified sequences were cloned into the pEGFP-N3 vector (Clontech Laboratories, Mountain View, CA) using the EcoRI-BamHI sites to generate CASQ1^{WT}-GFP and CASQ1^{MUT}-GFP vectors. Both cDNAs were also inserted into the pCDNA3 vector (Invitrogen, Carlsbad, CA) using the HindIII-BamHI sites to generate the CASQ1^{WT} and CASQ1^{MUT} expression vectors.

Cell Culture and DNA Transfection

COS-7 cells were cultured in DMEM containing 2 mM L-glutamine (Sigma-Aldrich), 100 μ g/ml streptomycin (Sigma-Aldrich), 100 U/ml penicillin (Sigma-Aldrich), 1 mM sodium pyruvate (Lonza Group, Basel, Switzerland), supplemented with 10% heat-inactivated fetal bovine serum (Sigma-Aldrich). Cells were grown at 37°C at 5% CO₂. COS-7 cells were plated on uncoated glass coverslips and transfected with X-tremeGENE HP DNA transfection Reagent (Roche Applied Science, Penzberg, Germany) according to manufacturer's instruction.

Myoblasts were obtained from hind limb muscles of 2-day-old rats (Sprague-Dawley; Harlan Laboratories, Indianapolis, IN) as described in Rossi et al. (2014). Cell suspension was plated on 0.025% laminin (Sigma-Aldrich) coated glass coverslips. Cells were grown at 37°C at 5% CO₂. After 2 days, cells were transfected with the Lipofectamine-Plus method (Life Technologies) following manufacturer's instruction. Myoblasts were induced to differentiate with Minimum Essential Medium Alpha containing 2 mM L-glutamine (Sigma-Aldrich), 100 μ g/ml streptomycin (Sigma-Aldrich), 100 U/ml penicillin (Sigma-Aldrich), 1 mM sodium pyruvate (Lonza), 1 mM dexamethasone (Sigma-Aldrich), 0.05 mM hydrocortisone, supplemented with 10% heat-inactivated fetal bovine serum (Sigma-Aldrich) and 5% heat-inactivated horse serum (Sigma-Aldrich).

Flexor Digitorum Brevis Fibers Electroporation with Plasmids Encoding CASQ1^{WT} and CASQ1^{MUT} Proteins

Mice were anesthetized with 1.25% 2,2,2-tribromoethanol (Avertin solution; Roche Applied Science) and flexor digitorum brevis (FDB) muscles injected with 10 μ g of DNA. Then, two electrodes were placed at each side of the muscle and electric pulses were delivered. Twenty 120 V electric pulses with fixed duration of 20 msec and interval of 1 sec were delivered using an electric pulse generator (Electro Square Porator ECM830; BTX-Genetronics, San Diego, CA-Genetronics, Inc.).

Results

Skeletal Muscle Fibers from Patients Present Vacuoles Containing Aggregates of SR Proteins

We analyzed eight patients (seven belonging to four different families and one unrelated sporadic case) affected by a mild myopathy accompanied by one or more symptoms, including episodes of muscle cramping, reduced muscle strength, fatigue, and elevated plasma creatine kinase (CK) levels. Light microscopy of muscle biopsies of all probands revealed, as a distinctive feature, the presence, mainly in type II fibers, of vacuoles that did not stain by routine histochemical analysis such as haematoxylin-eosin, Gomori-modified trichrome, and reduced nicotinamide adenine dinucleotide (NADH-TR) (Fig. 1A). Occasional necrotic fibers were also observed (not shown). In longitudinal semithin sections stained with toluidine blue, two different types of inclusions with characteristic staining properties and shape were noted: type-1 inclusions, consisting of a dark-stained material with a rectangular shape (Fig. 1A, panel 4, arrowhead), and type-2 inclusions, characterized by pale staining and a rounded profile (Fig. 1A, panel 4, arrow). Electron microscopy analysis (EM) showed the presence of inclusions filled with electron-dense material that resembles CASQ accumulation in the SR (Fig. 1B) [Jones et al., 1998; Paolini et al., 2011]. A significant percentage of fibers presented also areas rich in glycogen, various cytoplasmic debris, and abnormal mitochondria. In some sarcomeres, Z disks appeared not parallel to the M lines (Fig. 1B). EM quantitative analysis of the density and morphology/orientation of Ca²⁺ release units in biopsies from one patient and two healthy individuals showed that the density of Ca²⁺ release units per unit area is slightly decreased in the patient's fibers (24.1 \pm 1.3 vs. 30.3 \pm 0.9 per 100 μ m², respectively). Also, the general morphology of Ca²⁺ release units is changed: indeed a large percentage of triads (40.1 \pm 2.6% in patient vs. 5.8 \pm 1.1% in controls) appears to miss one SR element. Similar alterations have been described in human biopsies from elderly individuals [Boncompagni et al., 2006]. Finally, the average size of the SR terminal cisternae is slightly wider in the patient than in controls (105.6 \pm 1.9 nm vs. 86.4 \pm 0.9 nm, respectively, $P < 0.01$); this SR swelling could possibly represent an early step in the formation of inclusions. Occasional triads showing a bobbed junctional SR that appears clear and apparently empty were observed (Fig. 1B). Single fibers or cross-sections from patients' biopsies were stained with antibodies against CASQ1, RyR1, and SERCA. As shown in Fig. 1C, beside the cross striations typically observed with SR proteins, aggregates (consistent with inclusions found in EM), positive for all three antibodies were observed. Altogether, these results indicated that the inclusions present in muscle biopsies of the patients here reported are similar to those described in Tomelleri et al. (2006).




Figure 1. Morphological characterization of skeletal muscle fibers from patients. **A:** Hystological analysis. Hematoxylin–eosin (1), Gomori-modified trichrome (2), and NADH-TR (3) stainings of muscle fibers of patient II:1 of family 2. Longitudinal sections from a biopsy of patient II:3 of family 3 stained with toluidine blue (4) showing rectangular dark inclusions defined as type 1 (arrowhead), and round pale inclusion defined as type 2 (arrow) [Tomelleri et al., 2006]. Scale bars: panels 1–3 = 40 μm , panel 4 = 5 μm . **B:** Electron microscope analysis. Representative EM images of type 1 and type 2 inclusions from a biopsy of patient II:1 of family 2 (1 and 2) and of type 1 inclusions from a muscle biopsy of the sporadic patient (3). Representative EM images of patient II:3 of family 3 showing type 2 inclusions labeled with asterisks (4) and areas containing cytoplasmic debris and abnormal mitochondria (arrowheads in 5). The arrow (5) points to a misaligned Z disk. A vacuole clearly connected to the SR membrane of a Ca^{2+} release units is indicated with an arrow (6). Scale bars = 1 μm . **C:** Immunofluorescence analysis. Single muscle fibers (upper and middle panels) or cross-sections (lower panels) of skeletal muscle biopsy of patient I:1 of family 2 stained with antibodies against CASQ1, SERCA, and RyR1. Merged images show colocalization of CASQ1, RyR1, and SERCA in the aggregates. Scale bars = 2 μm .

A Common Variant in the *CASQ1* Gene is Present in All Patients

Sequence analysis of the *CASQ1* gene (NC_000001.11) in five probands revealed a heterozygous variant *c.731A>G* (Fig. 2A) resulting in an amino acid change from aspartic acid to glycine (p.Asp244Gly). Each CASQ1 molecule can bind 70–80 Ca^{2+} ions via high- and low-affinity Ca^{2+} -binding sites [Sanchez et al., 2012; Kumar et al., 2013]. Of notice, the aspartic acid 244 is conserved among orthologs in species from snakes to humans (Fig. 2B) and contributes to form one of the high-affinity Ca^{2+} -binding sites in CASQ1 [Sanchez et al., 2012]. Indeed, substitution of the aspartic acid at codon 244 to glycine is predicted to result in a conformational change in this Ca^{2+} -binding region (Fig. 2C). The variant segregated

with the disease phenotype in the four families analyzed (Fig. 2D). The *c.731A>G* variant was found in the 33-year-old proband of family 1, who had a history of mild myalgia, cramps and a fivefold increase of serum CK levels. The same symptoms were also reported for several proband's relatives, thus indicating recurrence of the disease. Unfortunately, DNA samples from other family members were not available for genetic analysis. The variant was also found in the 23-year-old proband of family 2, who showed mild proximal weakness in the upper limbs and increased serum CK levels, and in his affected father, who reported onset of clinical symptoms in his sixties with a mild increase in serum CK levels. The same variant was present also in the 58-year-old proband of family 3, who had a mild increase of serum CK levels (twofold to threefold the upper normal limit). Two years before, she had suffered painful contractures in the posterior left thigh muscles that spontaneously disappeared within 12 months. One sister (II:5) had a diagnosis of vacuolar myopathy made elsewhere, but EM examination of muscle fibers was not performed. The same symptoms were also reported for other members of this family, but DNA samples were not available for genetic analysis, with the exception of the proband's healthy daughter (III:2), who did not carry the *c.731A>G* variant. This family was already described in Tomelleri et al. (2006). The variant was detected in the 34-year-old proband of family 4, who presented mild myalgia on thighs at rest and increased CK levels (about sixfold the upper normal limit). The variant was also detected in his 57-year-old mother that presented an asymptomatic increase of serum CK level of about threefold the upper normal value. The brother of this proband was apparently healthy and presented normal CK values. Finally, the same variant was detected in one patient of 44 years, who reported a 10-month history of exercise-induced muscle pain, early fatigue in daily activities, and increased CK levels, about 16-fold the upper normal value. Unfortunately, no clinical information was available about relatives of this patient. In spite of the evidence that *Casq1* deletion in mice causes a MH-like phenotype, there was no family history of MH in these four families and screening of the *RYR1* gene did not result in the detection of MH-causative mutations in the five probands. Furthermore, screening of additional 93 patients including individuals with Idiopathic HyperCKemia and of 21 individuals with tubular-aggregate myopathy did not identify any variant in the *CASQ1* gene. The *c.731A>G* variant was not found in more than 400 control DNAs and is not reported in the 1000 genomes database (<http://www.1000genomes.org/>), in NHLBI Exome Sequencing Project Exome Variant Server (evs.gs.washington.edu/EVS/) or in dbSNP (<http://www.ncbi.nlm.nih.gov/projects/SNP/>).

Haplotype investigation was performed analyzing seven intra-genic SNPs (Supp. Table S1). Concerning families 2 and 4, homozygosity for all SNPs in one of the two analyzed individuals allowed us to reconstruct haplotypes, evidencing the presence of the same GGATGTA haplotype carrying the mutation. Conversely, in families 1 and 3, it was not possible to determine the correct phase for all SNPs. However, considering the high level of linkage disequilibrium present in this genomic region (HapMap data, release 27, phase II+III, Feb 9; <http://hapmap.ncbi.nlm.nih.gov/>), the observed genotypes at the polymorphic loci may be compatible with the same haplotype associated with the mutation in families 2 and 4 (Supp. Table S1), thus suggesting the existence of a common ancestor. We also analyzed the same SNPs in the sporadic patient; in this case, however, two SNPs (rs3747623 and rs822450) resulted to be incompatible with the haplotype associated with the mutation in families 2 and 4, thus suggesting the existence of a different haplotype. Noteworthy are the four families from two neighboring cities in the north east of Italy, whereas the sporadic patient is originally from an island in the south of Italy.




Figure 2. Genetic and molecular analysis of the p.Asp244Gly mutation. **A:** Electropherogram of the CASQ1 gene sequence of one patient. The patient is heterozygous for the c.731A>G variant (arrow). **B:** Phylogenetic alignment of the CASQ1 orthologs. The aspartic acid in position 244 in the human CASQ1 is highlighted yellow and is conserved in species ranging from snakes (*C. Adamanteus*) to humans. **C:** Three-dimensional structure of human CASQ1 protein. Ribbon representation of the model of chain A of the human CASQ1 three-dimensional structure (PDB:3UOM) with the Asp244 shown in red/dark (left). On the right, detailed views of predicted surface structure of the local molecular environments surrounding the Asp244 (upper panel) or the Gly244 residues (lower panel). The small (green) spheres represent Ca^{2+} ions. **D:** Pedigrees of families. Black-filled symbols represent affected family members. The genotype of individuals is shown in parenthesis as follows: Het, heterozygous for the c.731A>G variant; Hom wt, homozygous for the wild-type allele. Arrows indicate probands.




Figure 3. Ca^{2+} release kinetics in muscle fibers of two patients and expression of recombinant CASQ1^{WT} and CASQ1^{MUT} proteins. **A:** Ca^{2+} release kinetics in muscle fibers of two patients. Dose–response curves of permeabilized muscle fibers from control healthy subjects (black dashed line, average of 48 fibers from four subjects), patient I:1 of family 2 (continuous red line, average of 15 fibers), and from the sporadic case (continuous blue line, average of 21 fibers) exposed to increasing concentrations of caffeine (from 0.1 to 20 mM). Curves are interpolated by a sigmoidal Hill equation: $Y = B + \frac{(A_{\max} - B)}{1 + 10^{-(\log EC_{50-x}) * n}}$. The parameter $\log EC_{50}$ is significantly greater ($P < 0.01$) in the patient I:1 of family 2 (0.697 ± 0.062) and in the sporadic case (0.863 ± 0.101) than in controls (0.343 ± 0.006). **B:** CASQ1^{WT}-GFP and CASQ1^{MUT}-GFP were expressed in COS-7 cells. Living cells were imaged by confocal laser scan microscopy. Scale bars = 7 μm . **C:** Rat myotubes expressing recombinant CASQ1^{WT} and CASQ1^{MUT} were immunostained with antibodies against CASQ1 and RyR1. Scale bar = 2 μm . **D:** EM analysis of CASQ1^{WT} and CASQ1^{MUT} in mouse FDB fibers. Fibers expressing CASQ1^{MUT} show the presence of vacuoles filled with electron-dense material (asterisks). These vacuoles were not present in fibers expressing CASQ1^{WT}. Higher magnification shows enlarged vesicles derived from the SR-terminal cisternae: arrows point to RyR feet between an enlarged SR vesicle and a T-tubule. M, mitochondrion; TT, transverse tubule; SR, sarcoplasmic reticulum. Scale bars in left, middle, and right panels = 0.5, 1, and 0.1 μm , respectively.

Single Muscle Fibers from Two Patients with the p.Asp244Gly Mutation Show Altered Ca^{2+} Release Kinetics from the SR

To correlate SR alterations to the myopathic phenotype, the ability of taking up and releasing Ca^{2+} from the SR was studied in 15 single muscle fibers isolated from a biopsy of patient I:1 of family 2 (Fig. 2D) and in 21 fibers from a biopsy of the sporadic case, and compared with fibers dissected from four healthy subjects of comparable age. A protocol of cyclic SR loading in the presence of ATP at low pCa^{2+} and releasing Ca^{2+} with increasing concentrations of caffeine in low Mg^{2+} , low EGTA medium was applied [Salviati and Volpe, 1988]. Tension-time area was adopted as a reliable indicator of the amount of Ca^{2+} released [Endo and Iino, 1988; Salviati and Volpe, 1988; Lamb et al., 2001]. As can be seen in Figure 3A, average dose–response curves show that the amplitude of the maximal release (20 mM caffeine) was not significantly different in controls' and patients' fibers, whereas the responsiveness to caffeine was significantly reduced in a balanced pool of fast and slow fibers of both patients in comparison to a pool of healthy control fibers [Salviati and Volpe, 1988; Lamb et al., 2001]. While the similar maximal release in the probands' fibers and in the control fibers plays against reduced Ca^{2+} content of the SR, the difference in EC50 points to an altered regulatory action of CASQ1 on RyR1 opening.

Expression of Recombinant Mutated CASQ1 Protein Causes the Formation of Large Intracellular Aggregates

A cDNA coding for CASQ1 containing the Asp244Gly mutation was cloned in frame with the GFP sequence (CASQ1^{MUT}-GFP). As control, a GFP-tagged wild-type CASQ1 protein was generated (CASQ1^{WT}-GFP). Vectors expressing CASQ1^{MUT}-GFP and CASQ1^{WT}-GFP were transfected in COS-7 cells and fusion proteins visualized by confocal laser scan microscopy. As shown in Figure 3B, CASQ1^{WT}-GFP formed linear aggregates, which were never seen in cells expressing CASQ1^{MUT}-GFP protein (Fig. 3B). Generally, the CASQ molecule exists as either a monomer or a wide range of high molecular mass polymeric structures, depending on the ionic environment. Formation of polymers is mediated by front-to-front and back-to-back contacts between the CASQ monomers and is promoted by Ca^{2+} [Park et al., 2003; Kim et al., 2007]. The regular linear structures observed in cells expressing CASQ1^{WT}-GFP thus appear to reflect the assembly of large CASQ1 polymers in physiological Ca^{2+} concentration. On the contrary, lack of these linear structures in cells expressing CASQ1^{MUT}-GFP proteins suggests that the mutation affects CASQ1 polymerization. We next expressed the recombinant CASQ1^{WT} and CASQ1^{MUT} proteins, without the GFP tag, in cultured primary rat myoblasts that were induced to differentiate for 12 days. Staining with a monoclonal antibody against CASQ1 indicated that both proteins colocalized with RyR1 at the junctional

regions of the SR. However, CASQ1^{MUT} expression resulted also in the appearance of large intracellular aggregates strongly positive for CASQ1 (Fig. 3C), similar to those found in muscle biopsies of patients. Finally, EM analysis of mouse FDB fibers electroporated with vectors expressing CASQ1^{MUT} (Fig. 3D) showed the presence of inclusions containing electron-dense material similar to those observed in patients carrying the p.Asp244Gly mutation. The size of these inclusions was quite variable and a higher magnification revealed that (1) these are enlarged vesicles of SR origin as they are surrounded by a membrane and bear RyRs in the sites of contact with T-tubule (Fig. 3D), and (2) they are filled with an electron-dense matrix, which is identical to accumulation of overexpressed CASQ [Tomasi et al., 2012]. Similar aggregates were not found in fibers transfected with the CASQ1^{WT} protein (Fig. 3D).

Discussion

Protein aggregate myopathies are an emerging group of diseases characterized by structural abnormalities resulting from the aggregation of intrinsic proteins within muscle fibers. These aggregates are likely started by the aggregation of a mutant protein (e.g., desmin) that may also recruit additional normal proteins [Goebel and Blaschek, 2011]. The principles governing protein aggregation and induction of the structural alterations found within muscle fibers are still largely unknown. However, the recent identification of mutations in causative genes is shedding light on the molecular mechanisms that result in aggregate formation in these myopathies [North, 2008; Goebel and Blaschek, 2011; Schröder, 2013].

The p.Asp244Gly mutation in CASQ1, found in patients with a vacuolar myopathy characterized by distinctive SR protein aggregates in muscle fibers, represents the first mutation in CASQ1 linked to an inherited human muscle disease. This mutation affects the aspartic acid at position 244 in CASQ1 that, in addition to form a high-affinity Ca²⁺-binding site, is also close to a region of the protein proposed to be relevant for the interaction between adjacent monomers [Kim et al., 2007]. In close analogy with our results, the p.Arg33Gln mutation in CASQ2, identified in a patient with CPVT, appears also to affect a high-affinity Ca²⁺-binding site and to interfere with the assembly of longitudinal polymers, resulting in increased aggregate formation [Kim et al., 2007]. Indeed, several studies have been performed on both CASQ2 carrying mutations found in patients with CPVT and on CASQ1 containing selected mutations addressing specific structural domains: these mutated forms of CASQ showed an anomalous polymerization behavior, increased propensity to form aggregates, and displayed altered subcellular localization with reduced Ca²⁺-binding ability [Wang et al., 1998; Park et al., 2003; Cho et al., 2007; Kim et al., 2007; Subra et al., 2012]. It would then appear that mutations that alter Ca²⁺-binding ability and/or polymerization may reduce the ability of CASQ proteins to remain in solution and to efficiently store Ca²⁺ [Kim et al., 2007; Kumar et al., 2013]. Considering that CASQ1 polymers have a role in sustaining the rate of Ca²⁺ release in muscle contraction [Rossi and Dirksen, 2006], the reduced ability to polymerize and the increased tendency to form large aggregates observed in the CASQ1 mutant protein might explain the altered Ca²⁺ release kinetics observed in muscle fibers from two patients with the p.Asp244Gly mutation. These functional modifications, together with the overall structural alterations observed in muscle fibers from patients' biopsies, may then result in the myopathic phenotype observed. These results indicate that, similarly to what observed with other aggregate myopathies, the mutated CASQ1 might form the seed for aggregation of the other SR proteins detected in the inclusions observed

in patients with this myopathy. Thus, in agreement with previous terminology [Goebel and Blaschek, 2011; Schröder, 2013], we propose that this myopathy should be referred to as CASQ aggregate myopathy.

Acknowledgments

"The EuroBioBank and Telethon Network of Genetic Biobanks (GTB07001D) are gratefully acknowledged for providing biological samples." We thank Dr. Rosanna Asselta (University of Milan) for helpful advice and assistance in haplotype analysis.

References

- Boncompagni S, d'Amelio L, Fulle S, Fanò G, Protasi F. 2006. Progressive disorganization of the excitation-contraction coupling apparatus in ageing human skeletal muscle as revealed by electron microscopy: a possible role in the decline of muscle performance. *J Gerontol A Biol Sci Med Sci* 61:995–1008.
- Cho JH, Ko KM, Singaruvolu G, Lee W, Kang GB, Rho SH, Park BJ, Yu JR, Kagawa H, Eom SH, Kim do H, Ann J. 2007. Functional importance of polymerization and localization of calsequestrin in *C. elegans*. *J Cell Sci* 120:1551–1558.
- Dainese M, Quarta M, Lyfenko AD, Paolini C, Canato M, Reggiani C, Dirksen RT, Protasi F. 2009. Anesthetic- and heat-induced sudden death in calsequestrin-1-knockout mice. *FASEB J* 23:1710–1720.
- Damiani E, Volpe P, Margreth A. 1990. Coexpression of two isoforms of calsequestrin in rabbit slow-twitch muscle. *J Muscle Res Cell Motil* 11:522–530.
- Doria C, Toniolo L, Verratti V, Cancellara P, Pietrangelo T, Marconi V, Paoli A, Pogliaghi S, Fano G, Reggiani C, Capelli C. 2011. Improved VO₂ uptake kinetics and shift in muscle fiber type in high altitude trekkers. *J Appl Physiol* 111:1597–1605.
- Endo M, Iino M. 1988. Measurement of Ca²⁺ release in skinned fibers from skeletal muscle. *Methods Enzymol* 157:12–26.
- Galli L, Orrico A, Lorenzini S, Censini S, Falciani M, Covacci A, Tegazzin V, Sorrentino V. 2006. Frequency and localization of mutations in the 106 exons of the RYR1 gene in 50 individuals with malignant hyperthermia. *Hum Mutat* 27:830–839.
- Goebel HH, Blaschek A. 2011. Protein aggregation in congenital myopathies. *Semin Pediatr Neurol* 18:272–276.
- Jones LR, Suzuki YJ, Wang W, Kobayashi YM, Ramesh V, Franzini-Armstrong C, Cleemann L, Morad M. 1998. Regulation of Ca²⁺ signaling in transgenic mouse cardiac myocytes overexpressing calsequestrin. *J Clin Invest* 101:1385–1393.
- Kim E, Youn B, Kemper L, Campbell C, Milting H, Varsanyi M, Kang C. 2007. Characterization of human cardiac calsequestrin and its deleterious mutants. *J Mol Biol* 373:1047–1057.
- Kraeva N, Zvaritch E, Frodis W, Sizova O, Kraev A, MacLennan DH, Riazi S. 2013. CASQ1 gene is an unlikely candidate for malignant hyperthermia susceptibility in the North American population. *Anesthesiology* 118:344–349.
- Kumar A, Chakravarty H, Bal NC, Balaraju T, Jena N, Misra G, Bal C, Pieroni E, Periasamy M, Sharon A. 2013. Identification of calcium binding sites on calsequestrin 1 and their implications for polymerization. *Mol Biosyst* 9:1949–1957.
- Lahat H, Pras E, Olender T, Avidan N, Ben-Asher E, Man O, Levy-Nissenbaum E, Khoury A, Lorber A, Goldman B, Lancet D, Eldar M. 2001. A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. *Am J Hum Genet* 69:1378–1384.
- Lamb GD, Cellini MA, Stephenson DG. 2001. Different Ca²⁺ releasing action of caffeine and depolarisation in skeletal muscle fibres of the rat. *J Physiol* 531:715–728.
- MacLennan DH, Wong PT. 1971. Isolation of a calcium-sequestering protein from sarcoplasmic reticulum. *Proc Natl Acad Sci USA* 68:1231–1235.
- Makabe M, Werner O, Fink RH. 1996. The contribution of the sarcoplasmic reticulum Ca²⁺-transport ATPase to caffeine-induced Ca²⁺ transients of murine skinned skeletal muscle fibres. *Pflugers Arch* 432:717–726.
- North K. 2008. What's new in congenital myopathies? *Neuromuscul Disord* 18:433–442.
- Paolini C, Quarta M, D'Onofrio L, Reggiani C, Protasi F. 2011. Differential effect of calsequestrin ablation on structure and function of fast and slow skeletal muscle fibers. *J Biomed Biotech* 2011:634075.
- Park H, Wu S, Dunker AK, Kang C. 2003. Polymerization of calsequestrin. *J Biol Chem* 278:16176–16182.
- Protasi F, Paolini C, Canato M, Reggiani C, Quarta M. 2011. The lesson of calsequestrin-1 ablation in vivo: much more than a buffer, after all. *J Mus Res Cell Mot* 32:257–270.
- Rossi D, Barone V, Giacomello E, Cusimano V, Sorrentino V. 2008. The sarcoplasmic reticulum: an organized patchwork of specialized domains. *Traffic* 9:1044–1049.
- Rossi D, Bencini C, Maritati M, Benini F, Lorenzini S, Pierantozzi E, Scarcella AM, Paolini C, Protasi F, Sorrentino V. 2014. Distinct regions of triadin are required

- for targeting and retention at the junctional domain of the sarcoplasmic reticulum. *Biochem J* 458:407–417.
- Rossi AE, Dirksen RT. 2006. Sarcoplasmic reticulum: the dynamic calcium governor of muscle. *Muscle Nerve* 33:715–731.
- Salviati G, Volpe P. 1988. Ca^{2+} release from sarcoplasmic reticulum of skinned fast- and slow-twitch muscle fibers. *Am J Physiol* 254:C459–C465.
- Sanchez EJ, Lewis KM, Danna BR, Kang C. 2012. High-capacity Ca^{2+} binding of human skeletal calsequestrin. *J Biol Chem* 287:11592–11601.
- Schiaffino S, Reggiani C. 2011. Fiber types in mammalian skeletal muscles. *Physiol Rev* 91:1447–1531.
- Schröder R. 2013. Protein aggregate myopathies: the many faces of an expanding disease group. *Acta Neuropathol* 125:1–2.
- Subra AK, Nissen MS, Lewis KM, Muralidharan AK, Sanchez EJ, Milting H, Kang C. 2012. Molecular mechanisms of pharmaceutical drug binding into calsequestrin. *Int J Mol Sci* 13:14326–14343.
- Tomasi M, Canato M, Paolini C, Dainese M, Reggiani C, Volpe P, Protasi F, Nori A. 2012. Calsequestrin (CASQ1) rescues function and structure of calcium release units in skeletal muscles of CASQ1-null mice. *Am J Physiol Cell Physiol* 302:C575–C586.
- Tomelleri G, Palmucci L, Tonin P, Mongini T, Marini M, L'Erario R, Rizzuto N, Vattermi G. 2006. SERCA1 and calsequestrin storage myopathy: a new surplus protein myopathy. *Brain* 129:2085–2092.
- Wang S, Trumble WR, Liao H, Wesson CR, Dunker AK, Kang CH. 1998. Crystal structure of calsequestrin from rabbit skeletal muscle sarcoplasmic reticulum. *Nat Struct Biol* 5:476–483.